Literature DB >> 6815548

The benzodiazepine antagonist, Ro 15-1788, prevents the effects of flurazepam on the high pressure neurological syndrome.

A R Bichard, H J Little.   

Abstract

The benzodiazepine antagonist, Ro 15-1788, was used to investigate the anticonvulsant effect of flurazepam on the high pressure neurological syndrome (HPNS). Flurazepam raised the threshold pressures for the onset of tremor and of clonic convulsions caused by high pressure helium. Administration of the benzodiazepine antagonist Ro 15-1788 completely prevented the changes in threshold pressures produced by flurazepam. Alone, Ro 15-1788 did not affect the onset pressures. The concentration of Ro 15-1788 which blocked the actions of flurazepam on the pressure signs was the same as that required to prevent its effects on convulsions due to infusion of bicuculline. It is concluded that the effect of flurazepam on thresholds for the high pressure neurological syndrome is due to action at benzodiazepine receptors and not to a nonspecific effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6815548     DOI: 10.1016/0028-3908(82)90078-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  Systemically administered glycine protects against strychnine convulsions, but not the behavioural effects of high pressure, in mice.

Authors:  M J Halsey; H J Little; B Wardley-Smith
Journal:  J Physiol       Date:  1989-01       Impact factor: 5.182

2.  Reduction of flurazepam convulsive threshold by Ro 15-1788.

Authors:  W M Bourn; R L Garrett; C E Reigel; F O Risinger
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

3.  Interactions of the beta carboline abecarnil with the high pressure neurological syndrome in a primate model.

Authors:  P C Pearce; M J Halsey; C J MacLean; S Passingham; J Pearson; R L Mehta; B S Meldrum; C J Jordan; E M Ward
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.